Stockscreener 앱 받기
45.11
1.70%
-0.78
시간 외 거래:
45.14
0.03
+0.07%
전일 마감가:
$45.89
열려 있는:
$45.63
하루 거래량:
416.68K
Relative Volume:
1.20
시가총액:
$842.65M
수익:
$299.77M
순이익/손실:
$364.23M
주가수익비율:
2.4096
EPS:
18.7211
순현금흐름:
$79.27M
1주 성능:
+6.27%
1개월 성능:
+22.78%
6개월 성능:
+30.72%
1년 성능:
+8.70%
1일 변동 폭
$44.51
$46.21
1주일 범위
$41.37
$47.34
52주 변동 폭
$24.95
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
명칭
Rigel Pharmaceuticals
전화
650-624-1100
주소
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
45.11 | 845.26M | 299.77M | 364.23M | 79.27M | 18.72 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-05 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-04-03 | 재개 | Piper Sandler | Neutral |
| 2022-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-08 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | 개시 | B. Riley Securities | Neutral |
| 2020-11-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-15 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-09-26 | 재개 | JP Morgan | Overweight |
| 2019-03-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-08-27 | 개시 | Citigroup | Buy |
| 2018-05-02 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-12-21 | 재개 | Piper Jaffray | Overweight |
| 2017-12-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-06 | 재개 | H.C. Wainwright | Buy |
| 2017-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-31 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 재확인 | Piper Jaffray | Overweight |
| 2016-07-13 | 개시 | H.C. Wainwright | Buy |
| 2016-06-13 | 개시 | Piper Jaffray | Overweight |
| 2016-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2013-04-08 | 재확인 | Stifel | Buy |
| 2012-11-29 | 개시 | UBS | Neutral |
| 2012-11-06 | 재확인 | Oppenheimer | Outperform |
| 2012-03-26 | 개시 | Canaccord Genuity | Hold |
| 2010-12-10 | 다운그레이드 | MP Advisors | Outperform → Market Perform |
모두보기
Rigel Pharmaceuticals 주식(RIGL)의 최신 뉴스
Rigel (RIGL) Results Breakdown: EPS Exceeds Its Estimate for the Current Session; Market Reaction: Shares Finish 3.64% Down in Latest TradingSurprise Factor Analysis - Vinanet
Rigel Pharmaceuticals (NASDAQ:RIGL) Rating Increased to Hold at Zacks Research - MarketBeat
Rigel Pharmaceuticals (RIGL) Institutional Ownership 2026 $RIGL - MarketBeat
HC Wainwright Analysts Increase Earnings Estimates for RIGL - MarketBeat
RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside? - Stocktwits
Rigel Pharmaceuticals Inc (RIGL) (Q2 2026) Earnings Call Highlig - GuruFocus
Piper Sandler Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Raises Target Price to $49 - Moomoo
RIGL Maintains Neutral Rating -- Price Target Raised to $49.00 b - GuruFocus
Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope - Yahoo Finance
Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
(RIGL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
RIGL Maintained by HC Wainwright & Co. -- Price Target Raised to $85 - GuruFocus
Armistice Capital (RIGL) reports 1.67M Rigel Pharmaceuticals shares in 13G/A - Stock Titan
Rigel announces availability of Veppanu in the USA - The Pharma Letter
Rigel Says Breast Cancer Drug Veppanu Now Available in US, Puerto Rico - marketscreener.com
Rigel Pharmaceuticals (RIGL): Soleus Capital group discloses 9.9% ownership stake - Stock Titan
Rigel's VEPPANU Is Now Available for Certain Advanced Breast Cancers - Stock Titan
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer - PR Newswire
Rigel Pharmaceuticals, Inc. (RIGL) Latest Stock News & Headlines - finance.yahoo.com
Rigel (RIGL) Q2 2026 Earnings Call Transcript - The Globe and Mail
Rigel Pharmaceuticals (RIGL) Short Interest & Short Float | Updated Aug 2026 $RIGL - MarketBeat
Rigel Pharmaceuticals, Inc. $RIGL Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Janus Henderson Group PLC Boosts Position in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Rigel Pharmaceuticals Inc (RIGL) Stock News Today - TradingKey
Rigel Pharmaceuticals Inc (RIGL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HC Wainwright Issues Pessimistic Estimate for RIGL Earnings - MarketBeat
Pacer Advisors Inc. Purchases 48,882 Shares of Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Cantor Fitzgerald Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Raises Target Price to $43 - 富途牛牛
HC Wainwright Issues Pessimistic Forecast for RIGL Earnings - MarketBeat
Empowered Funds LLC Takes Position in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Rigel Pharmaceuticals (RIGL) Stock Rally Runs Into Earnings Quality Doubts - simplywall.st
Rigel Pharmaceuticals in-licenses Veppanu, targ... - Pluang
Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead (NASDAQ:RIGL) - Seeking Alpha
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - Moomoo
Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade) - Seeking Alpha
Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Up on Earnings Beat - MarketBeat
Rigel Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Rigel beats Q2 2026 estimates as VEPPANU launch nears - Investing.com
Is Rigel Pharmaceuticals (RIGL) Overvalued After Q2 Earnings Bea - GuruFocus
Rigel Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:RIGL) 2026-08-04 - Seeking Alpha
Rigel Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Rigel Pharmaceuticals (NASDAQ:RIGL) Posts Earnings Results, Beats Estimates By $0.79 EPS - MarketBeat
Rigel Pharmaceuticals : Quarterly Report for Quarter Ending JUNE 30, 2026 (Form 10-Q) - marketscreener.com
Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates - Yahoo Finance
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Q2 2026 Rigel Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Rigel Pharmaceuticals Q2 revenue rises on strong product demand - TradingView
Rigel Reports Second Quarter 2026 Financial Results - TradingView
Rigel Pharmaceuticals posts corporate deck highlighting VEPPANU in-license and commercial launch plan - Bitget
Rigel Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
Renaissance Technologies LLC Sells 200,568 Shares of Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Rigel Pharmaceuticals (RIGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
3.22%
자본화:
|
볼륨(24시간):